Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Identifying novel viruses or assessing viral variation by NGS requires high sequencing coverage. More than 90% of total RNA is ribosomal (rRNA), making variant calling, virus discovery or transcriptomic profiling difficult. Current methods to increase informative reads suffer from drawbacks, either they cannot be used for some viruses, are optimized for a single species, or introduce bias. We describe a two-part approach combining reverse-transcription to create RNA/DNA hybrids which are then degraded with RNaseH/DNase sequentially that works for three medically relevant mosquito genera; Aedes, Anopheles, and Culex. We demonstrate depletion of rRNA from different samples, including whole mosquitoes and midgut contents from FTA cards. We describe novel insect-specific virus genomes from field collected mosquitoes. The protocol requires only common laboratory reagents and small oligonucleotides specific to rRNA. This approach can be adapted for other organisms, aiding virus diversity analyses, virus discovery and transcriptomics in both laboratory and field samples.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934164PMC
http://dx.doi.org/10.1016/j.virol.2018.12.020DOI Listing

Publication Analysis

Top Keywords

virus discovery
8
reverse-transcription/rnase based
4
based protocol
4
protocol depletion
4
depletion mosquito
4
mosquito ribosomal
4
ribosomal rna
4
rna facilitates
4
facilitates viral
4
viral intrahost
4

Similar Publications

Deltaviruses are subviral agents of animals, which, in humans, require a hepadnavirus helper for transmission. The absence of deltavirus-like endogenous viral elements (δEVEs) has prevented an understanding of their evolution in deep time. By screening the representative genomes of all metazoans for endogenous delta antigen-like sequences, we report the discovery of 13 δEVEs in the genomes of five species of termites.

View Article and Find Full Text PDF

The European Health Data Space aims to transform health data management across the EU, supporting both primary and secondary uses of health data while ensuring trust through General Data Protection Regulation compliance. As part of the HealthData@EU Pilot, this study investigates coronavirus disease 2019 (COVID-19) testing, vaccination, and hospitalization metrics across six European countries, with a focus on socioeconomic disparities and challenges in cross-border data access and standardization. This observational, retrospective cohort study used a federated analysis framework across Belgium, Croatia, Denmark, Finland, and France.

View Article and Find Full Text PDF

The future European Health Data Space (EHDS), a network for secure cross-border data use, could be beneficial for public health initiatives. The HealthData@EU pilot project evaluated possibilities of secondary data use based on five use cases and established a pilot IT infrastructure. This article reports overarching experiences from two public health use cases and the IT development.

View Article and Find Full Text PDF

Manipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.

EMBO Mol Med

September 2025

State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, 100071, Beijing, China.

Traditional live attenuated vaccines (LAVs) are typically developed through serial passaging or genetic engineering to introduce specific mutations or deletions. While viral RNA secondary or tertiary structures have been well-documented for their multiple functions, including binding with specific host proteins, their potential for LAV design remains largely unexplored. Herein, using Zika virus (ZIKV) as a model, we demonstrate that targeted disruption of the primary sequence or tertiary structure of a specific viral RNA element responsible for Musashi-1 (MSI1) binding leads to a tissue-specific attenuation phenotype in multiple animal models.

View Article and Find Full Text PDF

Since its discovery, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has become the epicenter of public health concern. This was mainly attributed to the complexity of COVID-19 that resulted in variable disease progression with some developing asymptomatic infections, some suffering mild to moderate infections that resolved without the need for hospitalizations, and a few infected persons developing severe infections that required intensive care unit (ICU) admission and mechanical ventilation. The COVID-19 pandemic spread globally, affecting billions of people and killing millions.

View Article and Find Full Text PDF